litlas
Log inCreate account

Michael S. Ewer

Active 1980–2023

58
Papers
19,368
Citations
52
h-index
58
i10-index

Citations

Citations per year for Michael S. Ewer1980: 1 citations1982: 2 citations1983: 8 citations1984: 7 citations1985: 9 citations1986: 2 citations1987: 12 citations1988: 7 citations1989: 13 citations1990: 4 citations1991: 6 citations1992: 10 citations1993: 12 citations1994: 13 citations1995: 7 citations1996: 10 citations1997: 14 citations1998: 22 citations1999: 32 citations2000: 32 citations2001: 34 citations2002: 34 citations2003: 27 citations2004: 60 citations2005: 81 citations2006: 97 citations2007: 142 citations2008: 146 citations2009: 132 citations2010: 179 citations2011: 123 citations2012: 151 citations2013: 167 citations2014: 136 citations2015: 182 citations2016: 223 citations2017: 177 citations2018: 179 citations2019: 547 citations2020: 562 citations2021: 451 citations2022: 470 citations2023: 279 citations2024: 407 citations2025: 203 citations1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,549 citing papers, 26.9% of this breakdownChina: 459 citing papers, 8% of this breakdownItaly: 402 citing papers, 7% of this breakdownUnited Kingdom: 333 citing papers, 5.8% of this breakdownGermany: 251 citing papers, 4.3% of this breakdownCanada: 246 citing papers, 4.3% of this breakdownNetherlands: 183 citing papers, 3.2% of this breakdownFrance: 170 citing papers, 2.9% of this breakdownSpain: 166 citing papers, 2.9% of this breakdownBelgium: 139 citing papers, 2.4% of this breakdownJapan: 134 citing papers, 2.3% of this breakdownAustralia: 133 citing papers, 2.3% of this breakdown
0%26.9%Other 27.7%

Institutions

Fields

  • Medicine79.9%
  • Biochemistry, Genetics and Molecular Biology13.5%
  • Materials Science2.8%
  • Engineering1%
  • Computer Science0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other1.8%

Topics

  • Chemotherapy-induced cardiotoxicity and mitigation18%
  • Cancer Treatment and Pharmacology7%
  • HER2/EGFR in Cancer Research5.9%
  • Breast Cancer Treatment Studies4.6%
  • Cardiac Imaging and Diagnostics2.8%
  • Lung Cancer Research Studies2.5%
  • Other59.2%

Coauthors

All papers

Open in search
  1. Congestive heart failure in patients treated with doxorubicin

    Authors: Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer - Cancer 2003 cited by 2,284

  2. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Saro H. Armenian, Christina Lacchetti, Ana Barac, Joseph R. Carver, Louis S. Constine, Neelima Denduluri, Susan Dent, Pamela S. Douglas, Jean‐Bernard Durand, Michael S. Ewer, Carol J. Fabian, Melissa M. Hudson, Mariell Jessup, Lee W. Jones, Bonnie Ky, Erica L. Mayer, Javid J. Moslehi, Kevin C. Oeffinger, Katharine Ray, Kathryn J. Ruddy, Daniel J. Lenihan - Journal of Clinical Oncology 2017 cited by 1,263

  3. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

    Authors: Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jérusalem, Susan Dent, Linda Reaby, Hervé Bonnefoi, Ian E. Krop, Tsang‐Wu Liu, Tadeusz Pieńkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young‐Hyuck Im, Ling‐Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefanía Monturus, Mihaela Sicoe, Sébastien Guillaume, José Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen - Journal of Clinical Oncology 2021 cited by 359

  4. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

    Authors: Juan Carlos Plana, Maurizio Galderisi, Ana Barac, Michael S. Ewer, Bonnie Ky, Marielle Scherrer‐Crosbie, Javier Gáname, Igal A. Sebag, Deborah A. Agler, Luigi P. Badano, José Banchs, Daniela Cardinale, Joseph R. Carver, M. Cerqueira, Jeanne M. DeCara, Thor Edvardsen, Scott D. Flamm, Thomas Force, Brian P. Griffin, Guy Jérusalem, J. E. Liu, Andreia Magalhães, Thomas H. Marwick, Liza Sanchez, Rosa Sicari, Hector R. Villarraga, Patrizio Lancellotti - European Heart Journal - Cardiovascular Imaging 2014 cited by 1,783

  5. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

    Authors: Sandra M. Swain, Fredrick S. Whaley, Mirjam C. Gerber, Stuart P. Weisberg, Michael York, Darcy Spicer, Sarah E. Jones, Scott Wadler, Anjali Desai, Charles L. Vogel, James L. Speyer, A Mittelman, Salitha Reddy, Kelly Pendergrass, E Vélez-García, Michael S. Ewer, J. R. Bianchine, Richard A. Gams - Journal of Clinical Oncology 1997 cited by 652

  6. Cardiotoxicity of anticancer treatments

    Authors: Michael S. Ewer, Steven M. Ewer - Nature Reviews Cardiology 2015 cited by 414

  7. Erratum: Cardiotoxicity of anticancer treatments

    Authors: Michael S. Ewer, Steven M. Ewer - Nature Reviews Cardiology 2015 cited by 340

  8. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi, Sandra M. Swain, Charles E. Geyer, Michael S. Ewer, Vikas Rathi, Louis Fehrenbacher, Adam Brufsky, Catherine A. Azar, Patrick J. Flynn, John L. Zapas, Jonathan Polikoff, Howard M. Gross, David D. Biggs, James N. Atkins, Elizabeth Tan-Chiu, Ping Zheng, Greg Yothers, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2012 cited by 519

  9. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

    Authors: Sandra M. Swain, Michael S. Ewer, Giuseppe Viale, Suzette Delaloge, Jean-­Marc Ferrero, Mark Verrill, Rámón Colomer, Cláudia Vieira, Theresa L. Werner, Hannah Douthwaite, Denise Bradley, Maeve Waldron-Lynch, Astrid Kiermaier, Jennifer Eng‐Wong, Chau T. Dang - Annals of Oncology 2017 cited by 247

  10. Cardiovascular Complications of Cancer Therapy

    Authors: Edward T.H. Yeh, Ann T. Tong, Daniel J. Lenihan, Salim Yusuf, Joseph Swafford, Christopher Champion, Jean‐Bernard Durand, Harry Gibbs, Alireza Atef Zafarmand, Michael S. Ewer - Circulation 2004 cited by 851

  11. Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment

    Authors: Michael S. Ewer, Mary T. Vooletich, Jean‐Bernard Durand, Myrshia Woods, Joseph R. Davis, Vicente Valero, Daniel J. Lenihan - Journal of Clinical Oncology 2005 cited by 727

  12. Cancer drugs and the heart: importance and management

    Authors: Thomas Suter, Michael S. Ewer - European Heart Journal 2012 cited by 472

  13. Cardiac Safety of Osimertinib: A Review of Data

    Authors: Michael S. Ewer, Sri Harsha Tekumalla, Andrew Walding, Kwame N. Atuah - Journal of Clinical Oncology 2020 cited by 87

  14. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

    Authors: Michael S. Ewer, Steven M. Ewer - Nature Reviews Cardiology 2010 cited by 372

  15. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

    Authors: Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond, Charles E. Geyer, Michael S. Ewer, Deborah Keefe, Richard P. Shannon, Sandra M. Swain, Ann Brown, Louis Fehrenbacher, Victor G. Vogel, Thomas E. Seay, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark, John Bryant - Journal of Clinical Oncology 2005 cited by 807

  16. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Authors: Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis, Daniel J. Booser, Eva Thomas, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, Banu Arun, Sharon H. Giordano, Massimo Cristofanilli, Debra Frye, Terry L. Smith, Kelly K. Hunt, S. Eva Singletary, Ayşegül A. Şahin, Michael S. Ewer, Thomas A. Buchholz, Donald A. Berry, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2005 cited by 1,170

  17. Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity

    Authors: Michael S. Ewer, Scott M. Lippman - Journal of Clinical Oncology 2005 cited by 646

  18. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

    Authors: Atiar M. Rahman, Syed Wamique Yusuf, Michael S. Ewer - 2007 cited by 257

  19. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

    Authors: Sandra M. Swain, Fredrick S. Whaley, Mirjam C. Gerber, Michael S. Ewer, J. R. Bianchine, Richard A. Gams - Journal of Clinical Oncology 1997 cited by 269

  20. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

    Authors: Giuseppe Di Lorenzo, Riccardo Autorino, Gianni Bruni, Giacomo Cartenì, Enrico Ricevuto, Marianna Tudini, Corrado Ficorella, Carmela Romano, Michele Aieta, Antonio Giordano, Mario Giuliano, A. Gonnella, Cosimo De Nunzio, Mimma Rizzo, Vincenzo Montesarchio, Michael S. Ewer, Sabino De Placido - Annals of Oncology 2009 cited by 205

  21. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

    Authors: Jennifer R. Brown, Javid J. Moslehi, Michael S. Ewer, Susan O’Brien, Paolo Ghia, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Steven Coutré, Marie‐Sarah Dilhuydy, Paula Cramer, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Steven P. Treon, Emily Y. Liu, Stephen Chang, Amulya Bista, Rama Vempati, Lisa Boornazian, Rudolph Valentino, Vijay Reddy, Michelle Mahler, Huiying Yang, Thorsten Graef, Jan A. Burger - British Journal of Haematology 2018 cited by 90

  22. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

    Authors: Evandro de Azambuja, Elisa Agostinetto, Marion Procter, Daniel Eiger, Noam Pondé, Sébastien Guillaume, Damien Parlier, Matteo Lambertini, A. Desmet, Carmela Caballero, Christian Águila, Guy Jérusalem, Janice M. Walshe, Erica Frank, José Bines, Sibylle Loibl, Martine Piccart, Michael S. Ewer, Susan Dent, Chris Plummer, Thomas Suter - ESMO Open 2023 cited by 21

  23. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion

    Authors: Sewa S. Legha, Robert S. Benjamin, Bruce R. MacKay, Michael S. Ewer, Sidney Wallace, Manuel Valdivieso, Shelley L. Rasmussen, George R. Blumenschein, Emil J. Freireich - Annals of Internal Medicine 1982 cited by 769

  24. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.

    Authors: Michael S. Ewer, Mohammed K. Ali, Brendan J. MacKay, Sophie Wallace, María González Valdivieso, Sapna Legha, Robert S. Benjamin, Thomas P. Haynie - Journal of Clinical Oncology 1984 cited by 243